105 results about "Peptide modification" patented technology

The invention discloses a muscle-bone regeneration sustained-release preparation for targeting knee joint cartilage and a preparation process thereof, the preparation is composed of a cartilage targeting peptide modified PLGA-hyaluronic acid composite nanoparticle sustained-release carrier, an active regeneration component, a biocompatible matrix and an anti-inflammatory component, nanoparticles are prepared by a multiple emulsion solvent evaporation method, and targeting peptide is modified; the composite concentrated growth factors, stem cells and traditional Chinese medicine extracts have the functions of targeted enrichment, long-acting slow release, anti-inflammation and cartilage regeneration promotion, and can be used for knee joint cartilage defect repair.

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

This invention relates to biodetection technology, disclosing a peptide-modified gold nanocluster, its preparation method, and its application in the detection of microplastics. The peptide-modified gold nanocluster comprises a gold nanocluster and a peptide LCI modified on the surface of the gold nanocluster, wherein the peptide LCI comprises an amino acid sequence as shown in SEQ ID NO: 1. The preparation method includes the following steps: providing functionalized modified gold nanoclusters; reacting the functionalized gold nanoclusters with the peptide LCI to attach the peptide LCI to the surface of the gold nanoclusters, forming the peptide-modified gold nanocluster. The microplastic detection method includes mixing the peptide-modified gold nanocluster with a test sample that may contain microplastics to obtain a detection solution, and performing colorimetric analysis or absorbance analysis on the detection solution. This gold nanocluster can specifically recognize polypropylene, exhibiting good specificity, low cost, and rapid detection of polypropylene microplastics.

The invention discloses periodontitis targeted sustained-release gel based on epithelial training immunization and a preparation method thereof, and relates to the technical field of biological medicine, and the preparation method comprises the following steps: modifying poloxamer, and dissolving the modified poloxamer in anhydrous acetonitrile; the preparation method comprises the following steps: dissolving RGD peptide in a PBS (Phosphate Buffer Solution), adding N-hydroxysuccinimide and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and activating to obtain an activated RGD peptide solution; adding the activated RGD peptide solution into the modified poloxamer solution, and reacting at room temperature to obtain RGD peptide modified poloxamer; the RGD peptide modified poloxamer solution is mixed with a beta-glucan solution and a TLR2 agonist solution, and the periodontitis targeted slow-release gel is obtained. The gel provided by the invention specifically targets gingival epithelial cells, reduces inflammatory response and promotes periodontal tissue regeneration, has good biocompatibility and slow release performance, and can effectively control periodontitis and prevent relapse.

The application discloses an albumin nano-drug based on HSP90 inhibitor and a preparation method and application thereof, and belongs to the technical field of medicines.The short peptide A6 is modified to human blood albumin through a connecting chain, and the human blood albumin modified by the A6 is self-assembled with geldanamycin derivative G2111 in the presence of an organic solvent, so that the G2111 is combined to the hydrophobic region of the human blood albumin through a non-covalent bond, effective loading of the G2111 is realized, the solubility of the geldanamycin derivative is improved, the drug is targetedly released into cancer cells with high expression of CD44, the targeted accumulation of the drug in tumor tissues is enhanced, damage to other normal tissues and cells caused by off-target effects of the drug is avoided, the albumin nano-drug can be simultaneously used for chemotherapy of leukemia and solid tumors, and has important practical significance.

The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and / or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.

The application discloses a kind of polypeptide modified long afterglow nano-complex and its preparation method and application, nano-complex, for core-shell structure, core-shell structure is composed of the core body in inside and the shell that surrounds core body, core body is long afterglow nanomaterial, shell is by polypeptide modification and modified molecule modification, and drug loaded dendritic polymer;The nano-complex of the application can realize multiscale imaging to osteoclast, through in vivo afterglow imaging and in vivo two-photon microscopic imaging, the morphology, migration and distribution of osteoclast can be more accurately analyzed, avoid photo toxicity and background interference, improve imaging sensitivity;The nano-complex of the application is loaded with osteoporosis treatment drug alendronate ALN, and treatment drug can be replaced according to actual demand, and treatment scheme is adjusted, so that the drug loading system has universality.

An isolated peptide for regulating intracellular protein degradation that includes a linker sequence fused to a C-end degron peptide and, optionally, a caging molecule bonded to the carboxyl group of a C -terminal alanine residue. Also disclosed is a method for temporal control of protein degradation that relies on fusing a protein of interest at its C- terminus to the degron peptide having a caging molecule, and a method for high-fidelity gene editing that utilizes an RNA-dependent endonuclease modified at the C -terminus with the caged isolated peptide. A fusion protein for high-fidelity gene editing is further provided.

The application provides a zwitterionic polypeptide modified paclitaxel derivative, a prodrug nanocarrier micelle and a preparation method thereof, and belongs to the field of biological medicines. The preparation method comprises the following steps: mixing a zwitterionic polypeptide containing a sulfhydryl group with 2,2'-dithiodipyridine in a polar solvent, stirring and reacting, crystallizing, and obtaining a polypeptide derivative containing a disulfide bond; and then dissolving the polypeptide derivative and a sulfhydrylated paclitaxel (PTX-SH) in a polar solvent, adding glacial acetic acid to adjust the pH, stirring and reacting, and obtaining the paclitaxel derivative. The paclitaxel derivative is used for preparing a prodrug nanocarrier micelle by loading a hydrophobic anticancer drug, the prodrug nanocarrier micelle has a long blood circulation time in the body, a high drug loading capacity, small toxic side effects, excellent glutathione response and fast on-demand controlled release characteristics, and good tumor inhibition effect.

The invention discloses a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system, a preparation method and application thereof, and belongs to the technical field of biological medicine preparations, the nano delivery system comprises extracellular vesicles which can be genetically engineered by TRAIL and are derived from mammalian cells, and a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system and a stable GE11m peptide modified extracellular vesicle anti-cancer targeting nano delivery system, according to the present invention, the surface is connected with the D-type amino acid modified GE11m targeting peptide through the CP05 anchoring peptide, the amino acid sequence of the GE11m targeting peptide is YDHWYDGYTDPQNVI, and the first tyrosine, the fourth tyrosine and the seventh threonine in the GE11m peptide sequence are replaced with the D-type amino acid so as to significantly enhance the protease resistance and the serum stability of the targeting peptide.

The invention discloses a pathological microenvironment self-driven precise targeting nano-robot as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing an MOF carrier; (2) preparing MOF-coated ISLamp; a CORM-401 compound, and an organic solvent; (3) preparing apoptotic cell membranes; (4) preparing an FH peptide modified apoptosis cell membrane: coupling the FH peptide with a synthetic sequence of FHKHKSPALSPV with DSPE-PEG-NHS, then mixing with apM, carrying out ultrasonic treatment, and carrying out centrifugal purification to obtain FM; (5) preparing a nano robot: MOF (at) ISLamp; the CORM-401 and the FM membrane protein are mixed, asymmetrically wrapped, extruded to pass through a membrane, and centrifuged to obtain the nano-robot. According to the designed self-driven nano-robot integrating the triple functions of self-driving, precise targeting and collaborative treatment, CORM-401-ROS reaction is used for providing active power to break through a synovial membrane barrier, targeted enrichment of core pathological cells is achieved through an engineered cell membrane, the mitochondrial function is synergistically repaired by means of ISL and CO, OA pathological circulation is blocked, and the targeted enrichment of the core pathological cells is achieved. A brand new technical scheme is provided for treatment of osteoarthritis from symptomatic remission to pathological reversion.

This invention discloses an arginine-glycine-aspartic acid (RGD) peptide-modified chiral atomically precise metal nanoclusters, their preparation, and applications. The RGD peptide-modified chiral atomically precise metal nanoclusters consist of an atomically precise metal core, a chiral RGD peptide ligand layer, and linking molecules connecting the metal core and ligand layer. The chiral regulation and targeting functions of the RGD peptide-modified chiral atomically precise metal nanoclusters synergistically enhance their targeting and penetration at the tissue and cellular levels, thereby improving their uptake efficiency. After optimization with α... v The binding constant of β3 integrin is 1.4 × 10⁻⁶. ‑6 M ‑1 RGD peptides modify the ultrasmall metal cores of chiral atomically precise metal nanoclusters, endowing them with highly efficient and rapid renal clearance properties. This invention provides a solution suitable for various α-cell tumors, arthritis, liver fibrosis, and other conditions. v RGD peptides modified with chiral atomic precision metal nanoclusters, used to treat diseases with high expression of β3 integrin, can achieve efficient enrichment at target sites for imaging.

The invention relates to an MOTS-c targeted delivery system based on an exosome derived from astragalus membranaceus and application of the MOTS-c targeted delivery system in myocardial ischemia-reperfusion injury. The preparation method comprises the following steps: preparing an exosome AExo from radix astragali from fresh radix astragali as a raw material, modifying a cardiac troponin I targeting peptide LPFFD to the surface of the AExo by using an EDC / NHS chemical cross-linking method to obtain LPFFD-AExo, and loading a mitochondrial derived small peptide MOTS-c into the LPFFD-AExo by using an ultrasonic-assisted penetration method to obtain the LPFFD-AExo-MOTS-c. According to the invention, the accurate delivery efficiency of the damaged myocardial tissue can be improved, and efficient and accurate delivery of MOTS-c to the ischemia reperfusion damaged myocardial tissue is realized, so that the ferroptosis inhibition capability of MOTS-c is obviously enhanced, the myocardial protection effect on MI / R injury is improved, and finally efficient targeted therapy on MI / R injury is realized.

The invention discloses a TAT peptide modified photolyase liposome as well as a preparation method and application thereof, the method comprises the following steps: S1, mixing and dispersing phosphatidylserine, dipalmitoyl phosphatidyl glycerol, phosphatidic acid and glycerol to obtain a phospholipid-glycerol mixed phase; s2, dissolving photolyase and carboxymethyl chitosan, and adding the dissolved photolyase and carboxymethyl chitosan into the phospholipid-glycerol mixed phase to obtain a photolyase liposome; s3, mixing and dispersing the TAT peptide and the photolysis synthase liposome, so as to obtain the TAT peptide modified photolysis synthase liposome; the TAT peptide modified photolyase liposome has the advantages of mildness, no irritation and low cost, is non-toxic and has biological safety, the storage stability of the TAT peptide modified photolyase liposome can reach 90 days or above, transdermal absorption of active substances can be effectively promoted when the TAT peptide modified photolyase liposome is applied to biological drugs, and the application range of the TAT peptide modified photolyase liposome is widened.

A curcumin-containing nano-drug for treating cancer, a preparation method therefor, and use thereof. The nano-drug comprises curcumin and an extracellular vesicle expressing an anti-cancer protein TRAIL, or the nano-drug comprises curcumin and a tumor-antigen binding polypeptide-modified extracellular vesicle expressing an anti-cancer protein TRAIL. The curcumin is loaded into the extracellular vesicle for combined use, such that an extremely strong synergistic effect can be generated; the anti-cancer activity of the EV-T can be significantly enhanced by means of polypeptide modification; the composite nano-drug obtained by loading the curcumin into the extracellular vesicle can solve the problem of insolubility of curcumin, thereby further improving the anti-cancer effect.

The application discloses a pathological microenvironment self-driven precise targeted nanorobot and a preparation method and application thereof, and is prepared according to the following steps: (1) preparing a MOF carrier; (2) preparing a MOF@ISL&CORM-401 compound; (3) preparing an apoptotic cell membrane; (4) preparing an FH peptide modified apoptotic cell membrane: coupling FH peptide with a sequence of FHKHKSPALSPV and DSPE-PEG-NHS, mixing with apM under ultrasonic, centrifugal purification, and obtaining FM; (5) preparing a nanorobot: mixing the MOF@ISL&CORM-401 and the membrane protein of FM, asymmetrically wrapping, extruding through the membrane, and centrifugal to obtain the nanorobot. The self-driven nanorobot with the triple functions of self-driving, precise targeting and synergistic treatment is designed, the CORM-401-ROS reaction is utilized to provide active power to break through the synovial membrane barrier, the engineered cell membrane is utilized to realize the targeted enrichment of core pathological cells, the ISL and CO are utilized to repair the mitochondrial function, and the OA pathological cycle is blocked, so that a novel technical scheme is provided for the treatment of osteoarthritis from the symptomatic relief to the pathological reversal.

The invention discloses an engineered exosome of LTH peptide modified miR-146a-5p and application, the core component of the medicine is the engineered exosome, and the engineered exosome is constructed by the following method: miR-146a-5p mimic infected human renal tubular epithelium HK2 cells with nucleotide sequences shown as SEQ ID NO.1-SEQ ID NO.2 are cultured and screened, the exosome rich in miR-146a-5p is separated from the culture supernatant of the cells, and the exosome rich in miR-146a-5p is obtained. Then, the kidney targeting peptide LTH is modified on the surface of the exosome. The invention reveals that HNRNP M protein is a key molecule for regulating and controlling miR-146a-5p to be sorted and enter the exosome for the first time, and verifies that the engineered exosome can be efficiently enriched in kidney, and by delivering miR-146a-5p to target IRAK1 gene in macrophage and inhibiting TRAF6 / IKK / NF-kappa B inflammation signal pathway, the macrophage is promoted to be polarized to a repairable M2 phenotype, so as to realize the purpose of improving the activity of the miR-146a-5p. And finally, the kidney injury induced by the calcium oxalate crystal is effectively relieved. The medicine has the advantages of clear mechanism, strong targeting property, good biocompatibility and the like, provides a brand new immunoregulation treatment strategy for renal injury, and has a wide clinical application prospect.

This invention relates to the field of biomedical materials and pharmaceutical formulations, disclosing an FH peptide-polydopamine-coated graphene oxide drug delivery system and its preparation and application. The system includes an RGD peptide-modified graphene oxide carrier, a polydopamine shell, and a drug loaded within the system. The polydopamine shell is surface-modified with an FH peptide. The drugs include docetaxel and losartan, with docetaxel loaded on the RGD peptide-modified graphene oxide carrier and losartan loaded in the FH peptide-modified polydopamine shell. This FH peptide-polydopamine-coated graphene oxide drug delivery system, through surface modification of graphene oxide with an RGD peptide and coating with a polydopamine shell, effectively shields against the potential cytotoxicity and blood incompatibility risks of unmodified graphene oxide. Compared to unmodified graphene oxide carriers, this system shows significantly improved compatibility at both normal and tumor cell levels, maintaining extremely high cell viability across a wide concentration range.

The invention discloses an exosome and drug loaded gradient aperture periodontal regeneration composite membrane and a preparation method thereof, and belongs to the field of biomedical materials. According to the composite membrane, RGD peptide modified freeze-dried chitosan is adopted as an inner-layer macroporous membrane, silk fibroin loaded with periodontal ligament stem cell source exosome is adopted as a middle-layer mesoporous membrane, silk fibroin loaded with medicine is adopted as an outer-layer microporous membrane, and a three-layer gradient aperture structure is constructed through an electrostatic spinning and freeze-drying combined technology. The interlayer bonding strength is improved through interface spraying of polyvinyl alcohol, the biological activity is guaranteed through an exosome freeze-drying protection technology, and time sequence synergistic release of rapid anti-inflammation of drugs and long-acting regeneration promotion of exosomes is achieved. The composite membrane has excellent mechanical property, degradation property and biological activity, can remarkably promote gingival fibroblast COL-I secretion and alveolar bone regeneration, and is applied to periodontitis tissue regeneration and repair.

This specification describes a method for the late modification of peptides and functionalized peptides. The method is specific and robust and allows for the precise construction of C2-sulfenylated tryptophan using sulfenyl reagents such as thiosulfonic acid ester (ArSO2SR) reagents. This simple C2-sulfenylation process allows for the easy introduction of a variety of functional groups, such as SCF3, SCF2H, SCF2Br, SCHFCl, SCF2-alkyl groups, SCHF-alkyl groups, S-alkyl groups, and S-aryl groups, into peptides, particularly tryptophan residues of natural peptides. Generally, a late peptide modification method comprises (i) the step of maintaining a reaction mixture at a sufficient temperature for a sufficient time to produce a product. The reaction mixture comprises a peptide to be modified containing one or more tryptophan residues, a sulfenyl reagent, and a solvent. The product produced in step (i) comprises a sulfenylated peptide, wherein the sulfenylation has occurred in at least one of the one or more tryptophan residues of the peptide.

The application discloses a kind of based on ferroptosis and photodynamic cooperative treatment targeted laryngeal cancer nanoparticles and its preparation method and application.The nanoparticle is with polylactic acid-glycolic acid copolymer as carrier, co-loading photosensitizer indocyanine green and ferroptosis inducer Erastin, and realizes active targeting by cRGD peptide modification.Under laser irradiation, ICG produces reactive oxygen species and kills tumor cells, and Erastin induces ferroptosis by inhibiting GPX4 pathway, and the synergistic effect significantly enhances the anti-tumor effect.The application solves the problem of PDT hypoxic restriction and drug targeting deficiency, and PDT is combined with ferroptosis through nano-drug delivery platform, and the two promote each other, showing stronger anticancer effect, with high efficiency, stability and safety, suitable for targeted therapy of laryngeal squamous cell carcinoma.

The invention belongs to the technical field of antibiotic enzymes, and relates to a broad-spectrum antibiotic enzyme based on cation amphiphilic (KL) n oligopeptide modification and application thereof. The invention provides a broad-spectrum antibiotic enzyme, the structure of the broad-spectrum antibiotic enzyme comprises an antibiotic enzyme protein ECD7 and an analogue thereof, and a cationic amphiphilic oligopeptide (KL) n modified at the N end or the C end of the antibiotic enzyme protein ECD7 and the analogue thereof, and n in the cationic amphiphilic oligopeptide (KL) n is 5-8. The antibiotic enzyme provided by the invention has a good antibacterial effect on most of common pathogenic bacterial strains, and particularly has stronger antibacterial activity on gram-negative bacteria; in addition, the salt tolerance and fat solubility of the broad-spectrum antibiotic enzyme with the tail end modified with the cationic amphiphilic oligopeptide are remarkably improved, and the broad-spectrum antibiotic enzyme can adapt to wider and more complex production and practical application environments.

The invention discloses a small molecule peptide with cytotoxicity to breast cancer cells and application, and relates to the technical field of establishment and preparation of a small molecule peptide nano-drug delivery system. The small molecule peptide is a targeted peptide modified alkaline phosphatase reaction peptide, responds to ALP enzyme, is specifically combined with an integrin receptor, is self-assembled into spherical nanoparticles and serves as a nano drug carrier, and the structural formula is shown in figure 1. The research successfully designs and synthesizes a small molecule peptide with cytotoxicity to breast cancer cells, the small molecule peptide can be self-assembled into a nano NP drug delivery system, and an in-vitro experiment result shows that the self-assembled nano NP drug delivery system can quickly release chemotherapeutic drugs in an ALP overexpression environment, has small damage to healthy cells, is relatively low in cytotoxicity, and can be used for preparing a chemotherapeutic drug for treating breast cancer. However, the damage to cancer cells is obvious, and the action time of the medicine can be prolonged. An in-vivo anti-tumor experiment shows that compared with a non-deformable control peptide, the small molecule peptide drug loading system has a remarkable anti-tumor effect.

The present invention relates to peptide modifier compounds of Formula (1), or a salt thereof, wherein: a is an integer from 1 to 10, more preferably from 1 to 3; b is an integer from 0 to 7; Z is a terminal group and Y is a bivalent group. Further aspects of the invention relate to intermediates in the preparation of compounds of Formula (1), and the use of compounds of Formula (1) in the synthesis of peptide derivatives.

The invention belongs to the technical field of biological medicine and nano delivery, and particularly relates to a protein crown delivery system and a preparation method and application thereof. According to the protein crown delivery system provided by the invention, the specific bifunctional polypeptide is utilized to modify the surfaces of the gold nanoparticles, and various active proteins can be efficiently and stably combined to form the protein crown, so that the active proteins can be delivered in cells. Specifically, rich side chain groups of bifunctional polypeptide molecules are utilized to solve the problem of few binding sites between a protein crown delivery system and protein molecules, so that the protein crown delivery system and the protein molecules are combined and assembled through non-covalent interaction to form a uniform and stable protein crown structure, and the binding efficiency of a carrier and protein is improved; therefore, a universal, efficient and safe protein nano intracellular delivery carrier is constructed. The protein crown delivery system provided by the invention can be coupled with various types of proteins, and keeps the biological activity and function of the proteins, so that intracellular delivery can be performed on the proteins with different activities.

The invention belongs to the technical field of biological medicines, and particularly discloses a nano-drug for oral cancer as well as a preparation method and application of the nano-drug. The nano-drug provided by the invention is a drug-loaded mesoporous polydopamine nano-particle wrapped by a lipidosome modified by RGD peptide; wherein the load components of the mesoporous polydopamine nanoparticles comprise a cis-platinum drug and an RBMX gene expression inhibitor. The molecular RBMX related to regulation and control of oral cancer progress and cis-platinum drug resistance is screened, a nano biomimetic material drug loading system is constructed to load si-RBMX and cis-platinum to synergistically resist oral cancer treatment, and a novel nano drug with strong targeting property, good biological safety and excellent tumor lethality is obtained. The invention also provides a preparation method and application of the nano-drug.

The application discloses an electrochemical mediation method for glycine residue α The application discloses a method for realizing post-stage azaheteroarylation of a peptide by C-H functionalization, which realizes direct azaheteroarylation of a C-H bond under electrochemical conditions by using a controllable anodic oxidation approach α The strategy does not need a transition metal catalyst, avoids metal residues, and is particularly suitable for post-stage modification of a drug peptide and a biologically active molecule; the electrochemical indirect oxidation strategy is used, reaction conditions are mild, and functional group tolerance is excellent; direct post-stage modification of a complex molecule containing a glycine residue is realized, a synthesis route is simplified, and step economy is improved. In addition, the method not only has innovative value in a peptide modification method, but also provides an effective tool for exploring a biologically active molecule with further research potential, and azaheteroarylation products obtained by using the method have an inhibitory effect on a cancer cell line.

The present disclosure provides a nanobody platform having a high affinity purification on protein A, wherein the nanobodies may incorporate diverse bioactive peptides, lipid or glycoside in its CDR1 and / or CDR3 regions. The present disclosure also provides a peptide-modified nanobody comprising non-toxic bioactive peptides and that exhibit potent anti-tumor activity. Moreover, the peptide-modified nanobody is able to be combined with other technologies, such as but not limited to bispecific antibodies and antibody-drug conjugates. Further, the present disclosure also provides production processes of the nanobodies and their use as a treatment and diagnostic agents.

Applicants engineered peptide-modified AAV9 capsids for system-wide enhanced organ transduction by directly engineering a binding interaction with the human GPI-linked glycoprotein CD59. Adeno-associated vimses (AAVs) are used by numerous approved and investigational gene therapies. However, native AAVs have limited tissue tropisms and have comparatively low extrahepatic delivery efficiencies. While capsid engineering has largely focused on targeting specific organs, treating multisystem disorders requires efficient gene delivery to many organs. Here Applicants describe novel engineered capsids that bind CD59.